Dutasteride

Generic Name: Dutasteride

Brand Names: Avodart, Jalyn

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₃₀F_₆N_₂O_₂

CAS Number: 164656-23-9

Unique Ingredient Identifier: O0J6XJN02I

Background: Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. Type I and II 5α-reductase enzymes convert testosterone into dihydrotestosterone (DHT), a primary hormonal mediato...

Indication: Indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland to improve symptoms, and reduce the risk of acute urinary retention and the need for BPH-related surgery alone or in combination with tamsulosin.

Associated Conditions: Benign Prostatic Hyperplasia (BPH), Symptomatic benign prostatic hyperplasia (BPH)

Associated Therapies: -

Clinical Trials

Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate

Phase 4

Completed

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: dutasteride

First Posted Date: 2009-04-14

Last Posted Date: 2013-06-12

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 40

Registration Number: NCT00880672

Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction

Phase 4

Completed

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: Dutasteride

First Posted Date: 2009-01-23

Last Posted Date: 2009-06-11

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 36

Registration Number: NCT00827814

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation

Phase 4

Completed

Conditions: Prostate Cancer

Interventions: Drug: avodart
Drug: Placebo

First Posted Date: 2008-12-10

Last Posted Date: 2014-05-14

Lead Sponsor: Bay State Clinical Trials, Inc.

Target Recruit Count: 40

Registration Number: NCT00805701

Locations: 🇺🇸
Bay State Clinical Trials, Inc., Watertown, Massachusetts, United States

Pharmacokinetic Study of Single Dose Dutasteride in Healthy Subjects

Not Applicable

Completed

Conditions: Alcohol Related Disorders
Alcoholism
Alcohol Abuse

Interventions: Drug: Dutasteride

First Posted Date: 2008-12-04

Last Posted Date: 2010-09-23

Lead Sponsor: UConn Health

Target Recruit Count: 40

Registration Number: NCT00802321

Locations: 🇺🇸
Unversity of Connecticut Health Center, Farmington, Connecticut, United States

Prevention of Prostate Cancer With Dutasteride in Case of High Grade PIN Neoplasia

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: dutasteride
Procedure: prostate biopsy

First Posted Date: 2008-10-28

Last Posted Date: 2018-03-06

Lead Sponsor: Kaunas University of Medicine

Target Recruit Count: 200

Registration Number: NCT00780754

Locations: 🇱🇹
Urology dep. of Kaunas University of Medicine, Kaunas, Lithuania

Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement

Phase 4

Completed

Conditions: Hypogonadism

Interventions: Drug: placebo
Drug: dutasteride

First Posted Date: 2008-09-16

Last Posted Date: 2013-02-26

Lead Sponsor: The Miriam Hospital

Target Recruit Count: 24

Registration Number: NCT00752869

Locations: 🇺🇸
Men's Health Boston, Boston, Massachusetts, United States
🇺🇸
The Miriam Hospital, Providence, Rhode Island, United States

MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer

Not Applicable

Completed

Conditions: Nonmalignant Neoplasm
Prostate Cancer

Interventions: Drug: dutasteride

First Posted Date: 2008-06-30

Last Posted Date: 2014-01-17

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 10

Registration Number: NCT00706966

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart

Phase 4

Conditions: Benign Prostatic Hyperplasia

First Posted Date: 2008-06-05

Last Posted Date: 2008-06-05

Lead Sponsor: Urologic Consultants of Southeastern PA

Target Recruit Count: 50

Registration Number: NCT00690950

Locations: 🇺🇸
Urologic Consultants of Southeastern PA, Bala Cynwyd, Pennsylvania, United States

Treatment of Refractory Urinary Retention Secondary to Benign Prostatic Hyperplasia (BPH) With Dual Five Alpha Reductase Inhibition Combined With an Alpha Blocker

Not Applicable

Completed

Conditions: Urinary Retention
Benign Prostatic Hyperplasia

First Posted Date: 2008-05-20

Last Posted Date: 2008-05-20

Lead Sponsor: Franklin D. Gaylis, MD Inc.

Target Recruit Count: 20

Registration Number: NCT00680680

Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Dutasteride
Drug: Placebo

First Posted Date: 2008-04-29

Last Posted Date: 2023-08-22

Lead Sponsor: NorthShore University HealthSystem

Target Recruit Count: 20

Registration Number: NCT00668642

Locations: 🇺🇸
University of Chicago Hospitals and Clinics, Chicago, Illinois, United States
🇺🇸
Northwestern University Medical Center, Chicago, Illinois, United States
🇺🇸
NorthShore University HealthSystem, Evanston, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy